Abstract | BACKGROUND: METHODS: RESULTS: About 75% of the patients without concomitant using of tacrolimus ointment had blood levels of tacrolimus below the detection limit of the assay (0.5ng/mL). On the other hand, 71% (week 4) and 57% (week 12) of patients with concomitant using of tacrolimus ointment had blood levels above the detection limit of the assay. However, the maximum blood concentration was less than 2ng/mL. Adverse drug reactions occurred in 16 patients. These were disorders of the eye such as warmness, irritation, and a burning sensation. However, all of the patients could continue treatment with tacrolimus for 12 weeks. There were no serious adverse events such as increased intraocular pressure or ocular infection during the study. All symptoms and signs improved over time. CONCLUSIONS:
|
Authors | Nobuyuki Ebihara, Yuichi Ohashi, Hiroshi Fujishima, Atsuki Fukushima, Yayoi Nakagawa, Kenichi Namba, Shigeki Okamoto, Jun Shoji, Etsuko Takamura, Eiichi Uchio, Dai Miyazaki |
Journal | Allergology international : official journal of the Japanese Society of Allergology
(Allergol Int)
Vol. 61
Issue 2
Pg. 275-82
(Jun 2012)
ISSN: 1440-1592 [Electronic] England |
PMID | 22361511
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunosuppressive Agents
- Suspensions
- Tacrolimus
|
Topics |
- Adolescent
- Adult
- Child
- Conjunctivitis, Allergic
(blood, drug therapy, physiopathology)
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(administration & dosage, blood, pharmacokinetics)
- Male
- Prospective Studies
- Suspensions
- Tacrolimus
(administration & dosage, blood, pharmacokinetics)
- Treatment Outcome
- Young Adult
|